2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM
Coats C, Masri A, Nassif M, Barriales‐Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Düngen H, Garcia‐Pavia P, Hagège A, Januzzi J, Lee M, Lewis G, Ma C, Maron M, Miao Z, Michels M, Olivotto I, Oreziak A, Owens A, Spertus J, Solomon S, Tfelt‐Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby D, German P, Heitner S, Kupfer S, Lutz J, Malik F, Meng L, Wohltman A, Abraham T, Zhang Y, Yang H, Shao C, Yuan Z, Zeng Q, Li X, Wang Y, Shu Y, Chen M, Tao L, Li X, Wang J, Yu Z, Cheng X, Hong K, Zemanek D, Bundgaard H, Thune J, Jensen M, Mogensen J, Habib G, Charron P, Lhermusier T, Trochu J, Reant P, Logeart D, Mitrovic V, Bekfani T, Edelmann F, Seidler T, Meder B, Schulze P, Stoerk S, Rassaf T, Merkely B, Zfat‐Zwas D, Halabi M, Paz O, Piltz X, Metra M, Canepa M, Musumeci B, Emdin M, Amin A, Knackstedt C, Wojakowski W, Dudek D, Toste A, Bastos J, Blanes J, Urbano R, Alvarez A, Diaz L, Vera T, Elliott P, Glasgow N, Cooper R, Heart L, Mahmod M, Pantazis A, Esteban M, Health O, Marian A, Owens D, McGrew F, Bach R, Wever‐Pinzon O, Collado E, Turer A, Hannawi B, Geske J, Heart P, Symanski J, Heart S, Kramer C, Sarswat N, Ahmad F, Markowitz J, Lakdawala N, Jani S, Brinkley M, Bilen O, Asher C, Emani S, Sharma A, Fermin D, Lyle M, Raymer D, Darlington A, Nielsen C, Wang A, Nagueh S, Martinez M, Desai M, Tower‐Rader A, Kelly J, Heart A, Rader F, Sen S, Bering P, Maurer M, Mitter S, Sherrid M, Wong T, Hussain Z, Saberi S, Naidu S, Enciso J. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM. Journal Of The American Heart Association 2024, 13: e035993. PMID: 39056349, PMCID: PMC11964075, DOI: 10.1161/jaha.124.035993.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionObstructive hypertrophic cardiomyopathyTreatment-emergent adverse eventsHypertrophic cardiomyopathySafety profileAdverse eventsAtrial fibrillationLeft ventricular outflow tract gradientSymptomatic obstructive hypertrophic cardiomyopathyNew-onset atrial fibrillationImplantable cardioverter-defibrillator dischargeOutflow tract gradientCardioverter-defibrillator dischargeVentricular ejection fractionCardiac myosin inhibitorAdverse cardiac eventsLowest effective doseAdverse cardiovascular eventsDose reductionTreatment interruptionEjection fractionAficamtenDosing algorithmBaseline characteristicsCardiac events
2010
Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing
Roper N, Storer B, Bona R, Fang M. Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing. Journal Of Molecular Diagnostics 2010, 12: 283-291. PMID: 20228265, PMCID: PMC2860463, DOI: 10.2353/jmoldx.2010.090110.Peer-Reviewed Original ResearchConceptsPharmacogenetics-based dosing algorithmDosing algorithmInternational Warfarin Pharmacogenetics ConsortiumPercentage of patientsNarrow therapeutic windowDiverse ethnic populationsMaintenance dosesProspective trialWarfarin dosesWarfarin dosingPrescribed drugsPharmacogenetic testingWarfarin metabolismIWPC algorithmClinical utilityDosing rangeTherapeutic windowWarfarinGenetic testingPatientsGenetic polymorphismsExternal validationEthnic populationsService populationCYP2C9
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply